T-cell lymphoblastic lymphoma (T-LBL) is an aggressive malignancy of immature T cells characterized by rapid proliferation and frequent activation of pro-survival signaling pathways such as PI3K/AKT/mTORC1. Although multi-agent chemotherapy can induce remission in many patients, relapsed disease is commonly refractory, creating a need to identify molecular vulnerabilities that sensitize tumor cells to existing therapies. Prior genetic studies in mice implicated PIP4K family members in T-cell lymphomagenesis: loss of Pip4k2a and Pip4k2b protected Trp53-null mice from thymic lymphoma. Building on these observations, the present work examined how depletion of PIP4K2A and PIP4K2B affects signaling, proliferation, and response to chemotherapy in a human T-LBL cell line.
The authors used the Sup-T1 human T-LBL cell line and engineered doxycycline-inducible shRNAs to deplete PIP4K2A, PIP4K2B, or both. Effects on cell proliferation were monitored over time and compared between doxycycline-treated (+DOX) and untreated (−DOX) conditions. Drug response was assessed with dose–response or fixed-concentration assays for a panel of chemotherapeutic agents commonly relevant to T-LBL treatment. Signaling outcomes were evaluated by immunoblotting for phosphorylated AKT (pAKT), phosphorylated ACC (pACC), and phosphorylated S6K (pS6K) as readouts for AKT activity, ACC phosphorylation, and mTORC1 activity respectively.
Inducible knockdown of both PIP4K2A and PIP4K2B reduced Sup-T1 cell proliferation over 96 hours compared with controls. Combined depletion also increased sensitivity to the nucleoside analog nelarabine, with dose–response curves shifted toward greater growth inhibition when PIP4K2A/2B were depleted. Immunoblotting confirmed efficient doxycycline-inducible knockdown of each target and showed that combined depletion produced the strongest inhibitory effect on proliferation.
PIP4K2A/2B depletion broadly enhanced Sup-T1 sensitivity to a panel of chemotherapeutic agents. Dose–response experiments demonstrated increased sensitivity to antimetabolites (cytarabine, methotrexate, 6‑mercaptopurine), DNA-damaging agents (doxorubicin, etoposide, 4‑hydroperoxycyclophosphamide), as well as dexamethasone, L‑asparaginase, and vincristine. These data indicate that PIP4K2 depletion does not sensitize cells to a single drug class but rather augments the cytotoxicity of diverse agents used in T-LBL therapy.
When PIP4K paralogs were targeted individually, knockdown of PIP4K2A reproduced most of the enhanced chemosensitivity observed with combined PIP4K2A/2B depletion. PIP4K2A knockdown led to a marked increase in sensitivity to nelarabine and to fixed-concentration cytotoxicity assays with dexamethasone, doxorubicin, etoposide, and L‑asparaginase. By contrast, PIP4K2B knockdown produced more modest effects on proliferation and drug sensitivity. These results identify PIP4K2A as the dominant paralog mediating the observed phenotypes in Sup-T1 cells.
Immunoblot analyses revealed that PIP4K2A knockdown markedly reduced AKT phosphorylation, indicating decreased AKT signaling with PIP4K2A loss. PIP4K2B depletion produced a smaller reduction in pAKT. Regarding downstream mTORC1 signaling, individual knockdown of PIP4K2A or PIP4K2B produced only modest changes in S6K phosphorylation, whereas combined depletion of both kinases led to a pronounced decrease in pS6K, consistent with reduced mTORC1 activity. ACC phosphorylation did not increase correspondingly in these conditions. Together, these signaling data link PIP4K2A to positive regulation of AKT and suggest that dual loss of PIP4K2 paralogs more strongly suppresses mTORC1.
To test whether PIP4K2A kinase activity underlies the phenotypes, the authors treated Sup-T1 cells with two structurally distinct PIP4K2A inhibitors, 066ATZ and BAY-091. Neither inhibitor reduced Sup-T1 proliferation, altered nelarabine sensitivity, nor produced detectable decreases in AKT phosphorylation at the tested concentrations. Treatment of cells with PIP4K2B knockdown plus inhibitor also failed to recapitulate the effects of genetic depletion. The lack of response to catalytic inhibitors suggests that PIP4K2A supports AKT signaling and chemosensitivity through an activity-independent (non-catalytic) mechanism in this cellular context.
These data identify PIP4K2A as a positive regulator of AKT signaling in Sup-T1 T-LBL cells and show that depletion of PIP4K2A, alone or together with PIP4K2B, inhibits proliferation and enhances sensitivity to multiple chemotherapeutic agents. The failure of two distinct small-molecule PIP4K2A inhibitors to phenocopy genetic depletion implies a non-enzymatic role for PIP4K2A in maintaining AKT/mTORC1 pathway activity and chemotherapy resistance. The findings motivate further investigations into the molecular, non-catalytic functions of PIP4K2A in T-LBL and whether targeting those functions can be translated into therapeutic strategies.
Note: The source material provides experimental outcomes in Sup-T1 cells, immunoblot readouts for pAKT and pS6K, and effects of genetic knockdown and pharmacologic inhibitors as described above. Details such as exact experimental protocols, full quantitative values, or in vivo validation beyond the cited mouse genetic background were not reported in the provided source text.